Tier 3 — preclinical

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration

Ajla Hodzic Kuerec, Weilan Wang, Lin Yi, Rongsheng Tao, Zhigang Lin, Aditi Vaidya, Sohal Pendse, Sornaraja Thasma, Niranjan Andhalkar, Ganesh Avhad, Vidyadhar Kumbhar, Andrea B Maier
Mechanisms of Ageing and Development 2024 218:111917

Bibliography

PubMed
PMID 38430946
DOI
10.1016/j.mad.2024.111917
Funding
The parent clinical trial was fully funded by Aba Chemicals Co. and Abinopharm, Inc.
Competing interests
Lin Yi was an employee of Abinopharm; Rongsheng Tao and Zhigang Lin were employees of Aba Chemicals; the remaining authors declared no conflict of interest.

Study snapshot

DesignPost-hoc analysis of a randomized, double-blind, placebo-controlled dose-ranging clinical trial.
ModelGenerally healthy adults aged 40–65 years from the Yi 2023 NMN trial.
Samplen=80 parent-trial participants.
InterventionParent trial: placebo or NMN 300, 600 or 900 mg/day.
Duration60 days in the parent trial.
EndpointsInterindividual change in blood NAD; Six-minute walk test; SF-36; Blood biological-age estimate; HOMA-IR

What the study showed, in plain terms

This paper re-analyzed the 80-person Yi dose-ranging trial rather than running a new clinical trial. Its focus was why people differed so widely in the size of their blood-NAD response to NMN.

Blood NAD changes varied substantially between participants. Larger NAD increases were associated with better six-minute-walk and SF-36 changes, but those associations are post-hoc and cannot prove that a specific NAD target causes clinical improvement.

Key findings

  • Blood NAD response to NMN showed large interindividual variability.
  • Greater NAD increases were associated with larger improvements in six-minute-walk distance and SF-36 scores.
  • The analysis proposed monitoring NAD response as a potential approach to individualized dosing.
  • This report reuses the Yi 2023 trial cohort and should not be counted as a separate randomized trial.

What this study can and cannot tell us

The analysis was post-hoc, association-based and derived from an industry-funded parent trial. Correlations between NAD change and functional outcomes do not establish causality or a validated therapeutic NAD threshold.

Related papers in the corpus

Tier 2
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Lin Yi et al. · GeroScience · 2023

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology